TQB2303

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Diffuse Large B-cell LymphomaNon-hodgkin's Lymphoma

Phase 1

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Non-hodgkin's Lymphoma

Start: 2017-05-01End: 2018-06-30Target: 122Updated: 2018-03-07

Phase 3

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Diffuse Large B-cell Lymphoma

Start: 2019-01-10End: 2020-12-30Target: 230Updated: 2019-05-30